{"entity":{"id":"zl-1310","kind":"drug","name":"ZL-1310","aka":[],"tldr":"ZL-1310 is an experimental antibody-drug conjugate from Zai Lab (Shanghai) in phase 3 trials for non-small-cell lung cancer, aimed at DLL3.","summary":"ZL-1310 is an antibody-drug conjugate developed by Zai Lab (Shanghai). Its target is DLL3 (the sponsor names DLL3). The sponsor states: ZL-1310 is a DLL3-targeting antibody-drug conjugate (ADC), given as a single agent versus investigator's choice therapy (topotecan or amrubicin) in relapsed small cell lung cancer. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07218146 (A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)), in non-small-cell lung cancer. The largest, NCT07218146, plans to enrol 480 participants with primary completion expected 2028-06-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of ZL-1310","url":"https://clinicaltrials.gov/search?intr=ZL-1310"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["dll3"],"drugs":[],"companies":["zai-lab"],"institutions":[],"pathways":[],"terms":[],"trials":["dllevate","nct06885281"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["23 Sept 2026: the payload is not stated on any record OnCo reads, so the open drug engine shows ZL-1310 under DLL3 with the payload class not recorded rather than guessing."],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"ADC","mechanism":"ZL-1310 is a DLL3-targeting antibody-drug conjugate (ADC), given as a single agent versus investigator's choice therapy (topotecan or amrubicin) in relapsed small cell lung cancer.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/zl-1310/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/"}],"company":[{"id":"zai-lab","kind":"company","name":"Zai Lab","route":"/companies/zai-lab/"}],"trial":[{"id":"nct06885281","kind":"trial","name":"A Study of ZL-1310 in Participants With Selected Solid Tumors","route":"/trials/nct06885281/"},{"id":"dllevate","kind":"trial","name":"A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)","route":"/trials/dllevate/"},{"id":"nct07707895","kind":"trial","name":"DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers","route":"/trials/nct07707895/"}]}}